Posted by Michael Wonder on 30 Nov 2023
Oxford BioTherapeutics announces partner Boehringer Ingelheim received US FDA fast track designation for BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung
29 November 2023 - This is the third fast track designation for BI 764532.
Oxford BioTherapeutics today announces that the US FDA has granted fast track designation to BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung expressing DLL3 whose disease has progressed following at least one prior line of treatment including platinum-based chemotherapy.
